Trial Profile

A Two-year, Randomized, Controlled, Open-label, Virologic Response Adaptive Design, Multicenter Study to Optimize Antiviral Efficacy of Telbivudine in Adult Patients With HBeAg Positive Chronic Hepatitis B (EFFORT Study)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Apr 2020 According to an Assembly Biosciences media release, results of a retrospective analysis of patients from two Phase IV clinical trials (NCT00962533 and ISRCTN79659320) has been published in Hepatology, the journal of the American Association for the Study of Liver Diseases (AASLD).
06 Apr 2020 Results of a retrospective analysis of patients from two Phase IV clinical trials (NCT00962533 and ISRCTN79659320), presented in an Assembly Biosciences media release.
25 Mar 2020 Results published in the Journal of Infectious Diseases

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com